



Multicentric, open-label,
single-arm, Phase IV trial

The MINERVA Trial

Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer with focus on digital side effect management

HR+ HER2-

**Locally advanced or metastatic
breast cancer patients ***

1st line setting

n = 300

* pre- and postmenopausal patients (mandatory GnRH analogue in premenopausal patients)




Abemaciclib (Verzenios®)

+ Aromatase Inhibitor
(Letrozole, Anastrozole, Exemestane)

or

+ Fulvestrant

(investigator's choice)



Digital Side Effect Management

Symptom monitoring via
digital health application

CANKADO

for patient reported outcome
(patient diary and questionnaires)